Diagnosis and management of lower limb peripheral arterial disease: Summary of NICE guidance

BMJ (Online)

Volumn 345, Issue 7870, 2012, Pages

  Layden, Jennifer ^a   Michaels, Jonathan ^b   Bermingham, Sarah ^a   Higgins, Bernard ^a  

^a ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NAFTIDROFURYL OXALATE;

ANGIOPLASTY; ANKLE BRACHIAL INDEX; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; COST EFFECTIVENESS ANALYSIS; CRITICAL LIMB ISCHEMIA; DISEASE SEVERITY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LEG DISEASE; LEG REVASCULARIZATION; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT DURATION; ARTICLE; DIAGNOSTIC IMAGING; ISCHEMIA; LEG; METHODOLOGY; UNITED KINGDOM; VASCULARIZATION;

DIAGNOSTIC IMAGING; GREAT BRITAIN; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION;

EID: 84865225834     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4947     Document Type: Review

References (23)

1. Leng GC, Lee A, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-81.
2. Vascular Society of Great Britain and Ireland. The provision of services for patients with vascular disease. 2012. www.vascularsociety.org.uk/library/ vascular-society-publications.html.
3. National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease: diagnosis and managment. (Clinical guideline 147.) 2012. http://guidance.nice.org.uk/CG147.
4. National Institute for Health and Clinical Excellence. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. (Public health guidance PH10.) 2008. http://guidance.nice.org.uk/ PH10.
5. National Institute for Health and Clinical Excellence. Brief interventions and referral for smoking cessation in primary care and other settings. (Public health guidance PH1.) 2006. http://guidance.nice.org.uk/PH1.
6. National Institute for Health and Clinical Excellence. Varenicline for smoking cessation. (Technology appraisal 123.) 2007. http://guidance.nice.org. uk/TA123.
7. National Institute for Health and Clinical Excellence. Guidance on preventing the uptake of smoking by children and young people. (Public health guidance PH14.) 2008. http://guidance.nice.org.uk/PH14.
8. National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. (Clinical guideline 43.) 2006. http://guidance.nice.org. uk/CG43.
9. National Institute for Health and Clinical Excellence. Four commonly used methods to increase physical activity: brief interventions in primary care, exercise referral schemes, pedometers and community-based exercise programmes for walking and cycling. (Public health guidance PH2.) 2006. http://guidance.nice.org.uk/PH2.
10. National Institute for Health and Clinical Excellence. Intervention guidance on workplace health promotion with reference to physical activity. (Public health guidance PH13.) 2008. http://guidance.nice.org.uk/PH13.
11. National Institute for Health and Clinical Excellence. Guidance on the promotion and creation of physical environments that support increased levels of physical activity. (Public health guidance PH8.) 2008. http://guidance.nice. org.uk/PH8.
12. National Institute for Health and Clinical Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. (Clinical guideline 67.) 2008. http://guidance.nice.org.uk/CG67.
13. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease. (Technology appraisal 94.) 2006. http://guidance.nice.org.uk/TA94.
14. National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. (Technology appraisal 132.) 2007. http://guidance.nice. org.uk/TA132.
15. National Institute for Health and Clinical Excellence. The clinical effectiveness and cost effectiveness of patient education models for diabetes. (Technology appraisal 60.) 2003. http://guidance.nice.org.uk/TA60.
16. National Institute for Health and Clinical Excellence. Diagnosis and management of type 1 diabetes in children, young people and adults. (Clinical guideline 15.) 2004. http://guidance.nice.org.uk/CG15.
17. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). (Clinical guideline 66.) 2008. http://guidance.nice.org.uk/CG66.
18. National Institute for Health and Clinical Excellence. Diabetic foot - inpatient management of people with diabetic foot ulcers and infection. (Clinical guideline 119.) 2011. http://guidance.nice.org.uk/CG119.
19. National Institute for Health and Clinical Excellence. Preventing type 2 diabetes: population and community-level interventions in high-risk groups and the general population. (Public health guidance PH35.) 2011. http://guidance.nice.org.uk/PH35.
20. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. (Clinical guideline 127.) 2011. http://guidance.nice.org.uk/CG127.
21. National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal guidance 90). (Technology appraisal 210.) 2010. http://guidance.nice.org.uk/TA210.
22. National Institute for Health and Clinical Excellence. Guidelines manual. 2009. www.nice.org.uk/guidelinesmanual.
23. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2008. www.nice.org.uk/aboutnice/howwework/socialvaluejudgements/socialvaluejudgements. jsp.